Enhanced protective immune response to PCV2 subunit vaccine by co-administration of recombinant porcine IFN-¦Ã in mice

详细信息    查看全文

• 作者：Yi-Ping Wang ; Dan Liu ; Long-Jun Guo ; Qing-Hai Tang ; Yan-Wu Wei ; Hong-Li Wu ; Jian-Bo Liu ; Sheng-Bin Li ; Li-Ping Huang ; Chang-Ming Liu ; ^{lcm@hvri.ac.cn}
• 关键词：Porcine circovirus type 2 (PCV2) ; Capsid (Cap) protein ; Porcine interferon-gamma (PoIFN-¦Ã) ; Recombinant baculoviruses ; Immune response
• 刊名：Vaccine
• 出版年：2013
• 出版时间：21 January, 2013
• 年：2013
• 卷：31
• 期：5
• 页码：833-838
• 全文大小：514 K

文摘

The capsid (Cap) protein of PCV2 is the major immunogenic protein that is crucial to induce PCV2-specific neutralizing antibodies and protective immunity; thus, it is a suitable target antigen for the research and development of genetically engineered vaccines against PCV2 infection. IFN-¦Ã has exhibited potential efficacy as an immune adjuvant that enhances the immunogenicity of certain vaccines in experimental animal models. In this study, three recombinant proteins: PCV2-Cap protein, porcine IFN-¦Ã (PoIFN-¦Ã), and the fusion protein (Cap-PoIFN-¦Ã) of PCV2-Cap protein and PoIFN-¦Ã were respectively expressed in the baculovirus system, and analyzed by Western blot and indirect ELISA. Additionally, we evaluated the enhancement of the protective immune response to the Cap protein-based PCV2 subunit vaccine elicited by co-administration of PoIFN-¦Ã in mice. Vaccination of mice with the PCV2-Cap + PoIFN-¦Ã vaccine elicited significantly higher levels of PCV2-specific IPMA antibodies, neutralizing antibodies, and lymphocyte proliferative responses compared to the Cap-PoIFN-¦Ã vaccine, the PCV2-Cap vaccine, and LG-strain. Following virulent PCV2 challenge, no viraemia was detected in all immunized groups, and the viral loads in lungs of the PCV2-Cap + PoIFN-¦Ã group were significantly lower compared to the Cap-PoIFN-¦Ã group, the LG-strain group, and the mock group, but slightly lower compared to the PCV2-Cap group. These findings suggested that PoIFN-¦Ã substantially enhanced the protective immune response to the Cap protein-based PCV2 subunit vaccine, and that the PCV2-Cap + PoIFN-¦Ã subunit vaccine potentially serves as an attractive candidate vaccine for the prevention and control of PCV2-associated diseases.